Schizophrenia

Top Story

Prescription of second-generation, lower metabolic risk antipsychotics increases

May 21, 2017

SAN DIEGO — Findings presented here indicated that prescription of second-generation antipsychotics with lower metabolic risk have increased from 2006 to 2011, particularly for individuals with several metabolic disorders, but not those with cardiovascular disease.

“We know that patients with severe mental illness have a higher mortality rate than those without, estimates are between 13 and 30 years shorter life expectancy. That mortality gap has been widening in recent years,” Alisa Busch, MD, of McLean Hospital, said during a presentation. “Much of this excess mortality is due to medical comorbidity. We’ve known for a while now that second-generation antipsychotics can increase the risk for metabolic syndrome, which is a combination of different medical conditions —hypertension, hypercholesterolemia, diabetes and obesity — which in turn lead to increased risk for cardiovascular disease.”

Meeting News

Physician follow-up reduces hospital readmission in schizophrenia

May 20, 2017
SAN DIEGO — Timely follow-up with a physician reduced risk for early readmission among individuals with schizophrenia, particularly those with high-risk for…
FDA News

FDA approves generic Seroquel XR tablets

May 18, 2017
Pharmadax Inc. recently announced that the FDA approved a generic version of Seroquel XR tablets for schizophrenia and specific symptoms in bipolar disorder and…

Minerva advances phase 3, 4 trials of MIN-101 for schizophrenia

May 18, 2017
Following a recent meeting with the FDA, Minerva Neurosciences Inc. announced updated plans for phase 3 and 4 clinical development of MIN-101 for schizophrenia. …
CME

Psychotic Rampage Murderers, Part II: Psychotic Mania, Not Schizophrenia

Psychiatric Annals, May 2014, Volume 44 Issue 5
This provocative and controversial article addresses efforts at prevention of lethal psychotic rampages by challenging…
More »
CME

First-Episode Psychosis: November 2015

Keck School of Medicine of USC and Psychiatric Annals

Psychosis occurs first in young people and then can progress into a chronic lifelong disorder. Although some patients…
More »
Featured
American Psychiatric Association Annual Meeting

American Psychiatric Association Annual Meeting

Video
Meeting News Coverage

VIDEO: Recently approved Nuplazid fills treatment gap in Parkinson’s disease

May 25, 2016
More »
Meeting News

Prescription of second-generation, lower metabolic risk antipsychotics increases

May 21, 2017
SAN DIEGO — Findings presented here indicated that prescription of second-generation antipsychotics with lower metabolic risk have increased…

Meeting News

Physician follow-up reduces hospital readmission in schizophrenia

May 20, 2017
SAN DIEGO — Timely follow-up with a physician reduced risk for early readmission among individuals with schizophrenia, particularly those with…

FDA News

FDA approves generic Seroquel XR tablets

May 18, 2017
Pharmadax Inc. recently announced that the FDA approved a generic version of Seroquel XR tablets for schizophrenia and specific symptoms in bipolar…

Minerva advances phase 3, 4 trials of MIN-101 for schizophrenia

May 18, 2017
Following a recent meeting with the FDA, Minerva Neurosciences Inc. announced updated plans for phase 3 and 4 clinical development of MIN-101 for…

In the Journals

Study finds unintended consequences of disability benefits for schizophrenia

May 11, 2017
A coordinated specialty care intervention did not reduce likelihood of receiving Social Security Administration disability benefits among individuals…

In the Journals

Review supports long-term effects of antipsychotics for schizophrenia

May 10, 2017
A review conducted by experts in the field found little evidence of negative long-term effects of antipsychotics for schizophrenia and indicated…

Risperidone implant safe, effective for schizophrenia

May 1, 2017
BB0817, a 6-month risperidone implant, had comparable efficacy, safety and tolerability with oral risperidone, according to findings released by…

Meeting News

Neurocrine presents Ingrezza efficacy, safety data for tardive dyskinesia

April 27, 2017
At the American Academy of Neurology annual meeting, researchers presented long-term efficacy and safety data supporting the recent FDA approval of…

In the Journals

Study challenges overpruning hypothesis in schizophrenia

April 18, 2017
Recent findings indicated only smaller spines, not larger spines, were lost in deep layer 3 of the primary auditory cortex among individuals with…

FDA News

FDA approves Ingrezza for tardive dyskinesia

April 12, 2017
The FDA recently approved Ingrezza capsules for treatment of tardive dyskinesia in adults. “Tardive dyskinesia can be disabling and can…

More Headlines »
Advertisement
Advertisement